Recent News

• 02.03.2026 - Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
• 01.05.2026 - Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
• 11.04.2025 - Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
• 10.28.2025 - Longitudinal Analysis of B cell Remodeling in Systemic Lupus Erythematosus Following iPSC-derived CAR T-cell Therapy
• 10.26.2025 - iPSC-Derived, Off-the-Shelf anti-CD19 CAR T cells Deliver Improved Clinical Outcomes in Lupus with Reduced or No Conditioning Chemotherapy
• 10.26.2025 - Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy

Recent Filings

• 01.16.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.16.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.16.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.12.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.12.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.09.2026 - 144 Report of proposed sale of securities
• 01.09.2026 - 144 Report of proposed sale of securities
• 12.29.2025 - 144 Report of proposed sale of securities
• 11.13.2025 - 8-K Current report
• 11.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]